Dianthus price target raised to $63 from $56 at Raymond James

Raymond James raised the firm’s price target on Dianthus (DNTH) to $63 from $56 and keeps an Outperform rating on the shares. The topline readout for Dianthus’s Phase 2 MaGic study evaluating active C1s inhibitor, claseprubart, in acetylcholine receptor generalized myasthenia gravis showed competitive results vs. approved complement therapies on the MG-ADL registrational endpoint, the analyst tells investors in a research note. This result is meaningfully derisking of the CIDP and MMN programs for claseprubart, the firm says.